Background: Guidelines addressing the management of venous thromboembolism (VTE) in
cancer patients are heterogeneous and their implementation has been suboptimal …

Background Venous thromboembolism (VTE) often complicates the clinical course of
cancer. The risk is further increased by chemotherapy, but the trade‐off between safety and …

Background Neonates and children differ from adults in physiology, pharmacologic
responses to drugs, epidemiology, and long-term consequences of thrombosis. This …

This chapter about antithrombotic therapy in neonates and children is part of the
Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians Evidence …

The risk of thrombosis in children with acute lymphoblastic leukemia (ALL) reportedly ranges
between 1% and 37%. Epidemiologic studies have usually been hampered by small …

Background Intermittent locking of central venous catheters (CVCs) is undertaken to help
maintain their patency and performance. There are systematic variations in care: some …

Clotting factor transfusions are vital for people with diseases such as haemophilia. In the
1970s and 1980s, transfusions with pooled plasma led to a devastatingly high number of …

Objectives In preparation for a pediatric randomized controlled trial on thromboprophylaxis,
we determined the frequency of catheter‐related thrombosis in children. We also …

Antithrombin is a glycoprotein critical to the regulation of coagulation. Its primary action is the
inhibition of the activated coagulation factors IIa (thrombin) and Xa. In addition there is …

Thromboembolism is a serious complication of induction therapy for childhood acute
lymphoblastic leukemia. We prospectively compared the efficacy and safety of …